Logo image of ANRO

ALTO NEUROSCIENCE INC (ANRO) Stock Fundamental Analysis

USA - New York Stock Exchange - NYSE:ANRO - US02157Q1094 - Common Stock

16.5 USD
-0.44 (-2.6%)
Last: 1/13/2026, 8:04:00 PM
16.5 USD
0 (0%)
After Hours: 1/13/2026, 8:04:00 PM
Fundamental Rating

2

Overall ANRO gets a fundamental rating of 2 out of 10. We evaluated ANRO against 190 industry peers in the Pharmaceuticals industry. While ANRO seems to be doing ok healthwise, there are quite some concerns on its profitability. ANRO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ANRO has reported negative net income.
  • ANRO had a negative operating cash flow in the past year.
ANRO Yearly Net Income VS EBIT VS OCF VS FCFANRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • ANRO has a Return On Assets (-42.35%) which is in line with its industry peers.
  • ANRO's Return On Equity of -55.81% is in line compared to the rest of the industry. ANRO outperforms 50.00% of its industry peers.
Industry RankSector Rank
ROA -42.35%
ROE -55.81%
ROIC N/A
ROA(3y)-43.67%
ROA(5y)N/A
ROE(3y)-58.16%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ANRO Yearly ROA, ROE, ROICANRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ANRO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANRO Yearly Profit, Operating, Gross MarginsANRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -1K -2K -3K -4K -5K

More info and screens

6

2. Health

2.1 Basic Checks

  • ANRO has more shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, ANRO has an improved debt to assets ratio.
ANRO Yearly Shares OutstandingANRO Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M 25M
ANRO Yearly Total Debt VS Total AssetsANRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • ANRO has an Altman-Z score of 6.49. This indicates that ANRO is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 6.49, ANRO is in the better half of the industry, outperforming 77.89% of the companies in the same industry.
  • ANRO has a Debt/Equity ratio of 0.20. This is a healthy value indicating a solid balance between debt and equity.
  • ANRO's Debt to Equity ratio of 0.20 is in line compared to the rest of the industry. ANRO outperforms 44.21% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Altman-Z 6.49
ROIC/WACCN/A
WACCN/A
ANRO Yearly LT Debt VS Equity VS FCFANRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • ANRO has a Current Ratio of 15.42. This indicates that ANRO is financially healthy and has no problem in meeting its short term obligations.
  • ANRO's Current ratio of 15.42 is amongst the best of the industry. ANRO outperforms 85.26% of its industry peers.
  • A Quick Ratio of 15.42 indicates that ANRO has no problem at all paying its short term obligations.
  • ANRO has a Quick ratio of 15.42. This is amongst the best in the industry. ANRO outperforms 85.79% of its industry peers.
Industry RankSector Rank
Current Ratio 15.42
Quick Ratio 15.42
ANRO Yearly Current Assets VS Current LiabilitesANRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 76.51% over the past year.
EPS 1Y (TTM)76.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ANRO will show a small growth in Earnings Per Share. The EPS will grow by 3.27% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y9.82%
EPS Next 2Y2.72%
EPS Next 3Y-2.5%
EPS Next 5Y3.27%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANRO Yearly Revenue VS EstimatesANRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
ANRO Yearly EPS VS EstimatesANRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ANRO. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANRO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANRO Price Earnings VS Forward Price EarningsANRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANRO Per share dataANRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

  • ANRO's earnings are expected to decrease with -2.50% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.72%
EPS Next 3Y-2.5%

More info and screens

0

5. Dividend

5.1 Amount

  • ANRO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ALTO NEUROSCIENCE INC

NYSE:ANRO (1/13/2026, 8:04:00 PM)

After market: 16.5 0 (0%)

16.5

-0.44 (-2.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12
Earnings (Next)03-20
Inst Owners58.53%
Inst Owner Change0%
Ins Owners6.52%
Ins Owner Change0%
Market Cap512.65M
Revenue(TTM)N/A
Net Income(TTM)-62.26M
Analysts86.25
Price Target29.84 (80.85%)
Short Float %10.38%
Short Ratio3.35
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.85%
Min EPS beat(2)-3.96%
Max EPS beat(2)23.65%
EPS beat(4)3
Avg EPS beat(4)11.23%
Min EPS beat(4)-3.96%
Max EPS beat(4)23.65%
EPS beat(8)5
Avg EPS beat(8)-44.16%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)183.07%
EPS NQ rev (1m)0%
EPS NQ rev (3m)20.77%
EPS NY rev (1m)0%
EPS NY rev (3m)11.52%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.6
P/tB 4.6
EV/EBITDA N/A
EPS(TTM)-2.29
EYN/A
EPS(NY)-2.4
Fwd EYN/A
FCF(TTM)-1.73
FCFYN/A
OCF(TTM)-1.71
OCFYN/A
SpS0
BVpS3.59
TBVpS3.59
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.35%
ROE -55.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.67%
ROA(5y)N/A
ROE(3y)-58.16%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 78.64%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.42
Quick Ratio 15.42
Altman-Z 6.49
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)251.13%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.13%
EPS Next Y9.82%
EPS Next 2Y2.72%
EPS Next 3Y-2.5%
EPS Next 5Y3.27%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3.54%
EBIT Next 3Y-27.82%
EBIT Next 5Y-14.66%
FCF growth 1Y-91.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-90.64%
OCF growth 3YN/A
OCF growth 5YN/A

ALTO NEUROSCIENCE INC / ANRO FAQ

What is the ChartMill fundamental rating of ALTO NEUROSCIENCE INC (ANRO) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ANRO.


What is the valuation status of ALTO NEUROSCIENCE INC (ANRO) stock?

ChartMill assigns a valuation rating of 0 / 10 to ALTO NEUROSCIENCE INC (ANRO). This can be considered as Overvalued.


How profitable is ALTO NEUROSCIENCE INC (ANRO) stock?

ALTO NEUROSCIENCE INC (ANRO) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for ANRO stock?

The Earnings per Share (EPS) of ALTO NEUROSCIENCE INC (ANRO) is expected to grow by 9.82% in the next year.